Our research aims to improve the quality of life of patients with inflammatory bowel disease (IBD, including microscopic colitis, and also of patients with other gastrointestinal diseases. Exploring the molecular profile of these diseases is an integral part of projects performed in our research group. The overarching aim of our research is to identify markers for improved clinical decision making and to uncover pathophysiological mechanisms behind these markers or signatures of markers. Epidemiological and mechanistic links between various disease elements and across different phases of the diseases are examined. Our research programs are conducted in collaboration with national and international research groups, patient organisations, and private companies within the biomarker-, pharmaceutical- and digital sector.
/Jonas Halfvarson, MD, PhD
Professor of Gastroenterology and Consultant Gastroenterologist